Safety and Tolerability of Ezetimide - Reply

Main Article Content

Alice Y.Y. Cheng
MD FRCPC, Division of Endocrinology & Metabolism St. Michael's Hospital, Toronto, Ontario

Lawrence A. Leiter
MD FRCPC FACP Division of Endocrinology & Metabolism St. Michael's Hospital, Toronto, Ontario

Keywords

.

Abstract

.

Abstract 109 | PDF Downloads 64

References

1. Canadian Coordinating Office for Health Technology Assessment. Ezetimibe for lowering blood cholesterol. Issues in Emerging Health Technologies (newsletter) 2003;49:1-4. (Accessed March 2, 2004 at http://www.ccohta.ca/publications/pdf/ezeti mibe_cetap_e.pdf)
2. Masana L, Mata P, Gagne C, et al. Longterm safety and efficacy of ezetimibe added to ongoing simvastatin treatment. Atherosclerosis 2003;4(2):238-238. (Abst)

Article Sidebar

PDF
Published
Dec 9, 2018

Article Details

How to Cite
Cheng, A. Y., & Leiter, L. A. (2018). Safety and Tolerability of Ezetimide - Reply. Journal of Population Therapeutics and Clinical Pharmacology, 11(1). https://mail.jptcp.com/index.php/jptcp/article/view/580
Issue
Vol. 11 No. 1 (2004)
Section
Articles

All articles published in JPTCP  are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite

Cheng, A. Y., & Leiter, L. A. (2018). Safety and Tolerability of Ezetimide - Reply. Journal of Population Therapeutics and Clinical Pharmacology, 11(1). https://mail.jptcp.com/index.php/jptcp/article/view/580